Company Profile
Abbisko Cayman provides the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma
The development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer. Additionally, it develops drugs in Phase I/Ia clinical trial, including ABSK121 for solid tumors.
Its portfolio also includes ABSK112 for non-small cell lung and breast cancers, ABK3376 for non-small cell lung cancer, ABSK131 for solid tumors, ABSK141 for solid tumors, and ABSK051 for solid tumors ABSK012, which is in preclinical stage for the treatment of rhabdomyosarcoma and solid tumors. It also is involved in the development of drugs in IND enabling stage, such as ABSK211, ABSK191, and ABSK192 for solid tumors, as well as P151 for cardiometabolic
Drugs in lead optimization stage comprising P011, P018, P020, and P017 for solid tumors, as well as P023 for obesity and P022 for atopic dermatitis, asthma, and chronic obstructive pulmonary disease advisory and management services. Founded in 2016, Abbisko Cayman is headquartered in Shanghai, China.